| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Diuisione di Endocrinologia Ospedale Niguarda, Milan, Italy
Address all correspondence and requests for reprints to: Dr. Paola Loli, Divisione di Endocrinologia, Ospedale Niguarda, Piazza Ospedale Maggiore 3, 20162 Milan, Italy.
The therapeutic value of ketoconazole for long term treatment of patients with Cushing’s syndrome was studied. Seven patients with Cushing’s disease and one with an adrenal adenoma received 600–800 mg/day ketoconazole for 3–13 months. Plasma ACTH, cortisol, and dehydroepiandrosterone sulfate levels and urinary cortisol, 17-ketosteroid, and tetrahydro- 11-deoxycortisol excretion were determined periodically during the treatment period. Plasma ACTH and cortisol responses to CRH stimulation were determined before and during treatment. Rapid and subsequently persistent clinical improvement occurred in each patient; plasma dehydroepiandrosterone sulfate and urinary 17-ketosteroid and cortisol excretion decreased soon after the initiation of treatment, subsequently remaining normal or nearly so throughout the treatment period. Urinary tetrahydro-11-deoxycortisol excretion increased significantly. Plasma cortisol levels decreased. Plasma ACTH levels did not change, and individual plasma ACTH and cortisol increments in response to CRH were comparable before and during treatment. The cortisol response to insulin-induced hypoglycemia improved in one patient and was restored to normal in another. The seven patients tested recovered normal adrenal suppressibility in response to a low dose of dexamethasone during ketoconazole treatment.
Ketoconazole is effective for long term control of hypercortisolism of either pituitary or adrenal origin. Its effect appears to be mediated by inhibition of adrenal 11β-hydroxylase and 17,20- lyase, and it, in some unknown way, prevents the expected rise in ACTH secretion in patients with Cushing's disease. (J Clin Endocrinol Metab63: 1365, 1986)
Received May 13, 1986.
This article has been cited by other articles:
 |
|
 |
|
  B. M. K. Biller, A. B. Grossman, P. M. Stewart, S. Melmed, X. Bertagna, J. Bertherat, M. Buchfelder, A. Colao, A. R. Hermus, L. J. Hofland, et al. Treatment of Adrenocorticotropin-Dependent Cushing's Syndrome: A Consensus Statement J. Clin. Endocrinol. Metab., July 1, 2008; 93(7): 2454 - 2462. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F Castinetti, I Morange, P Jaquet, B Conte-Devolx, and T Brue Ketoconazole revisited: a preoperative or postoperative treatment in Cushing's disease Eur. J. Endocrinol., January 1, 2008; 158(1): 91 - 99. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Skov, K.M. Main, I.B. Sillesen, J. Muller, C. Koch, and S. Lanng Iatrogenic adrenal insufficiency as a side-effect of combined treatment of itraconazole and budesonide Eur. Respir. J., July 1, 2002; 20(1): 127 - 133. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. U. Freda and S. L. Wardlaw Diagnosis and Treatment of Pituitary Tumors J. Clin. Endocrinol. Metab., November 1, 1999; 84(11): 3859 - 3866. [Full Text]
|
|
|
|
 |
|
 O. M. Wolkowitz and V. I. Reus Treatment of Depression With Antiglucocorticoid Drugs Psychosom Med, September 1, 1999; 61(5): 698 - 711. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Guerin, A. Barbaud, M. Duquenne, N. Contet-Audonneau, F. Amiot, F. Ortega, and P. Hartemann Cushing's Disease and Cutaneous Alternariosis Arch Intern Med, September 1, 1991; 151(9): 1865 - 1868. [Abstract] [PDF]
|
|
|
|
|
|
G. Dickstein, A. Spindel, C. Shechner, F. Adawi, and H. Gutman Spontaneous Remission in Cushing's Disease Arch Intern Med, January 1, 1991; 151(1): 185 - 189. [Abstract] [PDF]
|
|
|
|
 |
|
 G. T. Tindall Neurological Surgery JAMA, May 19, 1989; 261(19): 2857 - 2858. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
